Cancers, Vol. 16, Pages 1479: Bevacizumab Treatment for Patients with NF2-Related Schwannomatosis: A Single Center Experience

Conclusion: Supporting previous studies, bevacizumab demonstrated positive effects on hearing, tumor control, and symptoms in NF2-related schwannomatosis, albeit with common adverse events. Therefore, careful consideration of an appropriate management strategy is warranted.

Source: Cancers - April 12, 2024 Category: Cancer & Oncology Authors: Jules P. J. Douwes Erik F. Hensen Jeroen C. Jansen Hans Gelderblom Josefine E. Schopman Tags: Article Source Type: research